NCT04764721View on ClinicalTrials.gov

Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID-19

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

August 15, 2023

Study Completion Date

November 27, 2023

Conditions
Covid-19
Interventions
DEVICE

18F-FDG PET-CT

Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT

Trial Locations (1)

54511

CHRU NANCY Brabois, nuclear medicine department, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT04764721 - Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID-19 | Biotech Hunter | Biotech Hunter